Barta JA, Powell CA, Wisnivesky JP (2019) Global epidemiology of lung cancer. Ann Glob Health 85(1):8. https://doi.org/10.5334/aogh.2419
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824
Garon EB (2016) The race for combined checkpoint inhibition in NSCLC. Lancet Oncol 17(3):259–260. https://doi.org/10.1016/S1470-2045(15)00580-X
Ellis PM, Vella ET, Ung YC (2017) Immune checkpoint inhibitors for patients with advanced non–small-cell lung cancer: a systematic review. Clin Lung Cancer 18(5):444-459.e1. https://doi.org/10.1016/j.cllc.2017.02.001
Article CAS PubMed Google Scholar
Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I keynote-001 study. JCO JCO.19.00934. https://doi.org/10.1200/JCO.19.00934
Champiat S, Dercle L, Ammari S et al (2016) Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-1741
Qin A, Street L, Cease K et al (2017) Clinical determinants of durable clinical benefit of pembrolizumab in veterans with advanced non–small-cell lung cancer. Clin Lung Cancer 18(5):559–564. https://doi.org/10.1016/j.cllc.2017.01.012
Article CAS PubMed PubMed Central Google Scholar
Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150. https://doi.org/10.1038/s41568-019-0116-x
Article CAS PubMed PubMed Central Google Scholar
Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.0393
Article PubMed PubMed Central Google Scholar
Georgieva M, da Silveira Nogueira Lima JP, Aguiar P, de Lima Lopes G, Haaland B (2018) Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. Lung Cancer 124:248–254. https://doi.org/10.1016/j.lungcan.2018.08.018
Bodor JN, Boumber Y, Borghaei H (2020) Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC). Cancer 126(2):260–270. https://doi.org/10.1002/cncr.32468
Article CAS PubMed Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774
Article CAS PubMed Google Scholar
Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697
Article CAS PubMed Google Scholar
Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13(9):1302–1311. https://doi.org/10.1016/j.jtho.2018.05.013
Article PubMed PubMed Central Google Scholar
Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med 376(25):2415–2426. https://doi.org/10.1056/NEJMoa1613493
Article CAS PubMed PubMed Central Google Scholar
Horn L, Spigel DR, Vokes EE et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35(35):3924–3933. https://doi.org/10.1200/JCO.2017.74.3062
Article CAS PubMed PubMed Central Google Scholar
Marcus L, Fashoyin-Aje LA, Donoghue M et al (2021) FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res 27(17):4685–4689. https://doi.org/10.1158/1078-0432.CCR-21-0327
Article CAS PubMed PubMed Central Google Scholar
Prasad V, Addeo A (2020) The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann Oncol 31(9):1112–1114. https://doi.org/10.1016/j.annonc.2020.07.001
Article CAS PubMed Google Scholar
Hellmann MD, Callahan MK, Awad MM et al (2018) Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33(5):853-861.e4. https://doi.org/10.1016/j.ccell.2018.04.001
Article CAS PubMed PubMed Central Google Scholar
Herbst RS, Giaccone G, de Marinis F et al (2020) Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. N Engl J Med. https://doi.org/10.1056/NEJMoa1917346
Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med 381(21):2020–2031. https://doi.org/10.1056/NEJMoa1910231
Article CAS PubMed Google Scholar
Herbst RS, Soria J-C, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. https://doi.org/10.1038/nature14011
Article CAS PubMed PubMed Central Google Scholar
Hu-Lieskovan S, Lisberg A, Zaretsky JM et al (2019) Tumor characteristics associated with benefit from pembrolizumab in advanced non–small cell lung cancer. Clin Cancer Res 25(16):5061–5068. https://doi.org/10.1158/1078-0432.CCR-18-4275
Article CAS PubMed PubMed Central Google Scholar
Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4(3):351–357. https://doi.org/10.1001/jamaoncol.2017.4771
Article PubMed PubMed Central Google Scholar
Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet 387(10030):1837–1846. https://doi.org/10.1016/S0140-6736(16)00587-0
Kamphorst AO, Pillai RN, Yang S et al (2017) Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. PNAS 114(19):4993–4998. https://doi.org/10.1073/pnas.1705327114
Article CAS PubMed PubMed Central Google Scholar
Sanmamed MF, Carranza-Rua O, Alfaro C et al (2014) Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20(22):5697–5707. https://doi.org/10.1158/1078-0432.CCR-13-3203
Article CAS PubMed Google Scholar
Guibert N, Delaunay M, Lusque A et al (2018) PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer 120:108–112. https://doi.org/10.1016/j.lungcan.2018.04.001
Indini A, Rijavec E, Grossi F (2021) Circulating biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review. Cancers 13(8):1794. https://doi.org/10.3390/cancers13081794
Article CAS PubMed PubMed Central Google Scholar
He X, Xu C (2020) Immune checkpoint signaling and cancer immunotherapy. Cell Res 30(8):660–669. https://doi.org/10.1038/s41422-020-0343-4
Article PubMed PubMed Central Google Scholar
Yarchoan M, Albacker LA, Hopkins AC et al (2019) PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4(6):126908. https://doi.org/10.1172/jci.insight.126908
Lee J, Hyeon DY, Hwang D (2020) Single-cell multiomics: technologies and data analysis methods. Exp Mol Med 52(9):1428–1442. https://doi.org/10.1038/s12276-020-0420-2
Article CAS PubMed PubMed Central Google Scholar
Stuart T, Satija R (2019) Integrative single-cell analysis. Nat Rev Genet 20(5):257–272. https://doi.org/10.1038/s41576-019-0093-7
Article CAS PubMed Google Scholar
Hartmann FJ, Bendall SC (2020) Immune monitoring using mass cytometry and related high-dimensional imaging approaches. Nat Rev Rheumatol 16(2):87–99. https://doi.org/10.1038/s41584-019-0338-z
Philip M, Schietinger A (2019) Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Curr Opin Immunol 58:98–103. https://doi.org/10.1016/j.coi.2019.04.014
Article CAS PubMed PubMed Central Google Scholar
Datar I, Sanmamed MF, Wang J et al (2019) Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis. Clin Cancer Res 25(15):4663–4673. https://doi.org/10.1158/1078-0432.CCR-18-4142
留言 (0)